Overview
BIIB market data
Price History
BIIB price chart
Valuation & Profitability
- P/E (TTM)
- 37.20 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $8.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 8.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $129.40 – $219.72 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $31B · P/B 1.41 · P/S 3.10.
Company News
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price TargetBenzinga · Aug 13, 2026, 5:18 PM
Biogen Completes Acquisition of RayThera Inc.Globenewswire Inc · Aug 6, 2026, 11:15 PM
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241Benzinga · Aug 4, 2026, 6:11 PM
Live On CNBC, Josh Brown Host Segment Titled “Josh’s Best Stocks In the Market: Incyte; Biogen"Benzinga · Aug 4, 2026, 4:36 PM
Why Supernus Pharmaceuticals Stock Topped the Market TodayThe Motley Fool · Aug 3, 2026, 11:15 PM
Citigroup Maintains Neutral on Biogen, Raises Price Target to $215Benzinga · Aug 3, 2026, 6:37 PM
UBS Maintains Buy on Biogen, Raises Price Target to $240Benzinga · Jul 30, 2026, 8:31 PM
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251Benzinga · Jul 30, 2026, 7:09 PM
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231Benzinga · Jul 30, 2026, 5:25 PM
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240Benzinga · Jul 30, 2026, 5:21 PM